An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Completed 166 enrolled Bristol-Myers Squibb

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.

Timeline

Start: 2016-06-17
Primary completion: 2020-11-02
Completion: 2020-11-02

Publications

Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu Q, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos FY, De Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 Jan 15;27(2):460-472. doi: 10.1158/1078-0432.CCR-20-1830. Epub 2020 Nov 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS 986178	Monoclonal antibody	—	—
Subject	Ipilimumab	Monoclonal antibody	—	—
Subject	Nivolumab	Monoclonal antibody	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	DPV-001 vaccine	Vaccine	—	—
Background	Tetanus vaccine	Vaccine	—	—

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Summary

Timeline

Publications

Drugs

Indications